OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
September 11, 2013
Novartis? half-billion dollar investment in a new biologics production plant in Singapore represents a strategic commitment to its growing biologics portfolio.
September 09, 2013
Mylan completes expansion of its transdermal patch facility in Vermont.
Sanofi and POZEN sign a license agreement for the commercialization of omeprazole and aspirin combination product.
September 06, 2013
Following passage in the California Assembly, the California State Senate passes legislation to specify requirements for dispensing biosimilars.
September 05, 2013
Merck & Co gets FDA approval to manufacture bulk varicella at its in Durham, North Carolina for use in chickenpox and shingles vaccines.
Baxter and Coherus Biosciences colaborate to develop and commercialize a biosimilar version of etanercept for Europe, Canada, and, Brazil.
September 04, 2013
Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.
Prequalification of Sanofi Pasteur?s Menomune vaccine makes it eligible for purchase by United Nations agencies.
September 03, 2013
Avacta?s Optim 2 instrument provides a practical solution for determining the conformational stability of adjuvant bound vaccines, eliminating the need for awkward and time consuming standard analytical techniques. [more?..]
September 02, 2013
The advantages of using an automated powder dispensing system in a ventilated balance enclosure for efficient handling and effective containment of potent compounds are discussed.